Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
Keyword(s):
2018 ◽
Vol 36
(15_suppl)
◽
pp. 4578-4578
Keyword(s):
2011 ◽
Vol 26
(3)
◽
pp. 273-277
◽
Keyword(s):
2008 ◽
Vol 31
(6)
◽
pp. 569-576
◽
Keyword(s):
1994 ◽
Vol 30
(12)
◽
pp. 1905-1907
◽
Keyword(s):
1990 ◽
Vol 1
(5)
◽
pp. 377-378
◽
Keyword(s):
2014 ◽
Vol 48
(4)
◽
pp. 379-386
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4682-4682
Keyword(s):